The insulin resistance syndrome (IRS) is considered to be a new target of risk-reduction therapy. The IRS is a cluster of closely associated and interdependent abnormalities and clinical outcomes that occur more commonly in insulin resistant/hyperinsulinemic individuals. This syndrome predisposes individuals to type 2 diabetes, cardiovascular diseases, essential hypertension, certain forms of cancer, polycystic ovary syndrome, nonalcoholic fatty liver disease, and sleep apnea. In patients at high risk for cardiovascular diseases, endothelial dysfunction is observed in morphologically intact vessels even before the onset of clinically mani fest vascular disease. Indeed, there are several lines of evidence that indicate that endothelial function is compromised in situations where there is reduced sensitivity to endogenous insulin. It is well established that a decreased bioavailability of nitric oxide (NO) contributes to endothelial dysfunction. Furthermore, NO may modulate insulin sensitivity. Activation of NO synthase (NOS) augments blood flow to insulin- sensitive tissues (i.e. skeletal muscle, liver, adipose tissue), and its activity is impaired in insulin resistance. Inhibition of NOS reduces the microvascular delivery of nutrients and blunts insulin-stimulated glucose uptake in skeletal muscle. Furthermore, induction of hypertension by administration of the NOS inhibitor NG-monomethyl-L-arginine is also associated with insulin resistance in rats. Increased levels of asymmetric dimethylarginine (ADMA) are associated with endothelial vasodilator dysfunction and increased risk of cardiovascular diseases. An intriguing relationship exists between insulin resistance and ADMA. Plasma levels of ADMA are positively correlated with insulin resistance in nondiabetic, normotensive people. New basic research insights that provide possible mechanisms underlying the development of insulin resistance in the setting of impaired NO bioavailability will be discussed.
Yeni-Komshian H., Carantoni M., Abbasi F., Reaven GMRelationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care2000; 23: 171-75.
2.
Lillioja S., Mott DM, Spraul M. et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians . N Engl J Med1993; 329: 1988-92.
3.
Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CRSlow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med1990; 113: 909-15.
4.
Reaven GMBanting lecture 1988. Role of insulin resistance in human disease . Diabetes1988; 37: 1595-607.
5.
Cooke JPThe endothelium: a new target for therapy. Vasc Med2000; 5: 49-53.
6.
Vincent MA, Barrett EJ, Lindner JR, Clark MG, Rattigan S.Inhibiting NOS blocks microvascular recruitment and blunts muscle glucose uptake in response to insulin. Am J Physiol Endocrinol Metab2003; 285: E123-9.
7.
Baron AD, Zhu JS, Marshall S., Irsula O., Brechtel G., Keech C.Insulin resistance after hypertension induced by the nitric oxide synthesis inhibitor L-NMMA in rats. Am J Physiol1995 ; 269: E709-15.
8.
Vallance P., Leone A., Calver A., Collier J., Moncada S.Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet1992; 339: 572-75.
9.
Achan V., Broadhead M., Malaki M. et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase . Arterioscler Thromb Vasc Biol2003; 23: 1455-59.
10.
Kielstein JT , Impraim B., Simmel S. et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans . Circulation2004; 109: 172-77.
11.
Cooke JPAsymmetrical dimethylarginine: the Uber marker? Circulation2004; 109: 1813-18.
12.
Valkonen VP , Paiva H., Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet2001; 358: 2127-28.
13.
Zoccali C., Bode-Böger S., Mallamaci F. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet2001; 358: 2113-17.
14.
Stühlinger MC, Abbasi F., Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor . JAMA2002; 287: 1420-26.
15.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation2002; 106: 3143-421.
16.
Reaven G.The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am2004; 33: 283-303.
17.
McLaughlin T., Abbasi F., Lamendola C. et al. Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation2002; 106: 2908-12.
18.
Meigs JB, Mittleman MA, Nathan DM et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA2000; 283: 221-28.
19.
Chen NG, Abbasi F., Lamendola C. et al. Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy nondiabetic volunteers. Circulation1999; 100: 940-43.
20.
Chen NG, Holmes M., Reaven GMRelationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers. J Clin Endocrinol Metab1999; 84: 3485-89.
21.
Baron ADVascular reactivity. Am J Cardiol1999; 84: 25J-27J.
22.
Joannides R. , Haefeli WE, Linder L. et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation1995; 91: 1314-19.
23.
Huang PL, Huang Z., Mashimo H. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature1995; 377: 239-42.
24.
Shesely EG, Maeda N., Kim HS et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A1996; 93: 13176-81.
25.
Forte P., Copland M., Smith LM, Milne E., Sutherland J., Benjamin N.Basal nitric oxide synthesis in essential hypertension. Lancet1997; 349: 837-42.
26.
Vita JA, Treasure CB, Nabel EG et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation1990; 81: 491-97.
27.
Anderson TJ , Uehata A., Gerhard MD et al. Close relation of endothelial function in the human coronary and peripheral circulations . J Am Coll Cardiol1995; 26: 1235-41.
28.
Schachinger V., Britten MB, Zeiher AMPrognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation2000; 101: 1899-906.
29.
Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T.Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation2001; 104: 2673-78.
30.
Healy B.Endothelial cell dysfunction: an emerging endocrinopathy linked to coronary disease. J Am Coll Cardiol1990; 16: 357-58.
31.
Pinkney JH, Stehouwer CD, Coppack SW, Yudkin JSEndothelial dysfunction: cause of the insulin resistance syndrome . Diabetes1997; 46(Suppl 2): S9-13.
32.
Steinberg HO , Chaker H., Leaming R., Johnson A., Brechtel G., Baron ADObesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance . J Clin Invest1996; 97: 2601-10.
33.
Laakso M., Edelman SV, Brechtel G., Baron ADDecreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest1990; 85: 1844-52.
34.
Quinones MJ , Hernandez-Pampaloni M., Schelbert H. et al. Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med2004; 140: 700-708.
35.
Modan M., Halkin H., Almog S. et al. Hyperinsulinemia: a link between hypertension, obesity and glucose intolerance. J Clin Invest1985; 75: 809-17.
36.
Lucas CP, Estigarribia JA, Darga LL, Reaven GMInsulin and blood pressure in obesity. Hypertension1985; 7: 702-706.
37.
Shen DC, Shieh SM, Fuh MM, Wu DA, Chen YD, Reaven GMResistance to insulin-stimulated-glucose uptake in patients with hypertension . J Clin Endocrinol Metab1988; 66: 580-83.
38.
Marigliano A., Tedde R., Sechi LA, Pala A, Pisanu G, Pacifico A. Insulinemia and blood pressure. Relationships in patients with primary and secondary hypertension, and with or without glucose metabolism impairment . Am J Hypertens1990; 3: 521-26.
39.
Laakso M., Edelman SV, Brechtel G., Baron ADImpaired insulin-mediated skeletal muscle blood flow in patients with NIDDM . Diabetes1992; 41: 1076-83.
40.
Baron ADHemodynamic actions of insulin. Am J Physiol1994; 267: E187-202.
Taddei S., Virdis A., Mattei P., Natali A., Ferrannini E., Salvetti A.Effect of insulin on acetylcholine-induced vasodilation in normotensive subjects and patients with essential hypertension. Circulation1995; 92: 2911-18.
43.
Vincent MA, Dawson D., Clark AD et al. Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes2002; 51: 42-48.
44.
Vincent MA, Clerk LH, Lindner JR et al. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes2004; 53: 1418-23.
45.
Nesher R., Karl IE, Kipnis DMDissociation of effects of insulin and contraction on glucose transport in rat epitrochlearis muscle. Am J Physiol1985 ; 249: C226-32.
46.
Lee AD, Hansen PA, Holloszy JOWortmannin inhibits insulin-stimulated but not contraction-stimulated glucose transport activity in skeletal muscle. FEBS Lett1995; 361: 51-54.
47.
Balon TW, Nadler JLEvidence that nitric oxide increases glucose transport in skeletal muscle . J Appl Physiol1997; 82: 359-63.
48.
Young ME, Radda GK, Leighton B.Nitric oxide stimulates glucose transport and metabolism in rat skeletal muscle in vitro. Biochem J1997; 322(Pt 1): 223-28.
49.
Etgen GJ, Fryburg DA, Gibbs EMNitric oxide stimulates skeletal muscle glucose transport through a calcium/contraction- and phosphatidylinositol-3-kinase-independent pathway . Diabetes1997; 46: 1915-19.
50.
Steinberg HO , Brechtel G., Johnson A., Fineberg N., Baron ADInsulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest1994; 94: 1172-79.
51.
Baron AD, Tarshoby M., Hook G. et al. Interaction between insulin sensitivity and muscle perfusion on glucose uptake in human skeletal muscle: evidence for capillary recruitment . Diabetes2000; 49: 768-74.
52.
Chen YL, Messina EJDilation of isolated skeletal muscle arterioles by insulin is endothelium dependent and nitric oxide mediated. Am J Physiol1996; 270: H2120-24.
53.
Sartori C., Trueb L., Nicod P., Scherrer U.Effects of sympathectomy and nitric oxide synthase inhibition on vascular actions of insulin in humans. Hypertension1999; 34: 586-89.
54.
Scherrer U. , Randin D., Vollenweider P., Vollenweider L., Nicod P.Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest1994; 94: 2511-15.
55.
Duplain H., Burcelin R., Sartori C. et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation2001; 104: 342-45.
56.
Singh S., Evans TWNitric oxide, the biological mediator of the decade: fact or fiction?Eur Respir J1997; 10: 699-707.
57.
Knowles RG, Moncada S.Nitric oxide as a signal in blood vessels. Trends Biochem Sci1992; 17: 399-402.
58.
Zeng G., Quon MJInsulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest1996; 98: 894-98.
59.
Zeng G., Nystrom FH, Ravichandran LV et al. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation2000; 101: 1539-45.
60.
Montagnani M. , Chen H., Barr VA, Quon MJInsulin-stimulated activation of eNOS is independent of Ca2 + but requires phosphorylation by Akt at Ser(1179) . J Biol Chem2001; 276: 30392-98.
61.
Bergandi L., Silvagno F., Russo I. et al. Insulin stimulates glucose transport via nitric oxide/cyclic GMP pathway in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol2003; 23: 2215-21.
62.
Ohlstein EH , Wood KS, Ignarro LJPurification and properties of heme-deficient hepatic soluble guanylate cyclase: effects of heme and other factors on enzyme activation by NO, NO-heme, and protoporphyrin IX. Arch Biochem Biophys1982;218:187-98.
63.
Winder WW, Hardie DGInactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am J Physiol1996; 270: E299-304.
64.
Corton JM, Gillespie JG, Hardie DGRole of the AMP-activated protein kinase in the cellular stress response . Curr Biol1994; 4: 315-24.
65.
Kudo N., Barr AJ, Barr RL, Desai S., Lopaschuk GDHigh rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem1995; 270: 17513-20.
66.
Chen ZP, Mitchelhill KI, Michell BJ et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett1999; 443: 285-89.
67.
Fryer LG, Hajduch E., Rencurel F. et al. Activation of glucose transport by AMP-activated protein kinase via stimulation of nitric oxide synthase. Diabetes2000; 49: 1978-85.
68.
Higaki Y., Hirshman MF, Fujii N., Goodyear LJNitric oxide increases glucose uptake through a mechanism that is distinct from the insulin and contraction pathways in rat skeletal muscle . Diabetes2001; 50: 241-47.
69.
Baron AD, Clark MGRole of blood flow in the regulation of muscle glucose uptake. Annu Rev Nutr1997; 17: 487-99.
70.
Yamamoto H. , Bossaller C., Cartwright J., Henry PDVideomicroscopic demonstration of defective cholinergic arteriolar vasodilation in atherosclerotic rabbit. J Clin Invest1988; 81: 1752-58.
71.
Kaley G., Rodenburg JM, Messina EJ, Wolin MSEndothelium-associated vasodilators in rat skeletal muscle microcirculation . Am J Physaol1989; 256: H720-25.
72.
Shankar R., Zhu JS, Ladd B., Henry D., Shen HQ, Baron ADCentral nervous system nitric oxide synthase activity regulates insulin secretion and insulin action. J Clin Invest1998; 102: 1403-12.
73.
Shankar RR, Wu Y., Shen HQ, Zhu JS, Baron ADMice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes2000; 49: 684-87.
74.
Lundman P., Eriksson MJ, Stuhlinger M., Cooke JP, Hamsten A., Tornvall P.Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine . J Am Coll Cardiol2001; 38: 111-16.
75.
Lin KY, Ito A., Asagami T. et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase . Circulation2002; 106: 987-92.
76.
Abbasi F., Asagami T., Cooke JP et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol2001; 88: 1201-203.
77.
Matsuoka H. , Itoh S., Kimoto M. et al. Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension . Hypertension1997; 29: 242-47.
78.
Surdacki A. , Nowicki M., Sandmann J. et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol1999; 33: 652-58.
79.
Asagami T., Abbasi F., Stuehlinger M. et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism2002; 51: 843-46.
80.
Pistrosch F. , Passauer J., Fischer S., Fuecker K., Hanefeld M., Gross P.In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care2004; 27: 484-90.
81.
Ryan MJ, Didion SP, Mathur S., Faraci FM, Sigmund CDPPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension2004; 43: 661-66.
82.
Katakam PV, Ujhelyi MR, Hoenig M., Miller AWMetformin improves vascular function in insulin-resistant rats. Hypertension2000; 35: 108-12.
83.
Mather KJ, Verma S., Anderson TJImproved endothelial function with metformin in type 2 diabetes mellitus . J Am Coll Cardiol2001; 37: 1344-50.
84.
Dayoub H., Achan V., Adimoolam S. et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation2003; 108: 3042-47.
85.
Lillioja S. , Young AA, Culter CL et al. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man . J Clin Invest1987; 80: 415-24.
86.
Lithell H., Lindgarde F., Hellsing K. et al. Body weight, skeletal muscle morphology, and enzyme activities in relation to fasting serum insulin concentration and glucose tolerance in 48-year-old men. Diabetes1981; 30: 19-25.
87.
Jansson PA, Fowelin JP, von Schenck HP, Smith UP, Lonnroth PNMeasurement by microdialysis of the insulin concentration in subcutaneous interstitial fluid. Importance of the endothelial barrier for insulin. Diabetes1993; 42: 1469-73.
88.
Castillo C. , Bogardus C., Bergman R., Thuillez P., Lillioja S.Interstitial insulin concentrations determine glucose uptake rates but not insulin resistance in lean and obese men. J Clin Invest1994 ; 93: 10-16.
89.
Miles PD, Levisetti M., Reichart D., Khoursheed M., Moossa AR, Olefsky JMKinetics of insulin action in vivo. Identification of rate-limiting steps . Diabetes1995; 44: 947-53.
90.
Kapur S., Bedard S., Marcotte B., Cote CH, Marette A.Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes1997; 46: 1691-700.
91.
Balon TWRole of nitric oxide in contraction induced glucose transport. Adv Exp Med Biol1998; 441: 87-95.
92.
Roy D., Perreault M., Marette A.Insulin stimulation of glucose uptake in skeletal muscles and adipose tissues in vivo is NO dependent. Am J Physiol1998 ; 274: E692-99.
